Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Licenses Stem Cell Patents

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis today said that it has licensed intellectual property covering induced Pluripotent Stem Cells (iPSCs) from iPS Academia Japan.

The non-exclusive licensing deals cover research conducted by Shinya Yamanaka of the Center for iPS Cell Research and Application at Kyoto University in Japan. iPS Academia Japan is an affiliate of Kyoto University established in 2008 to manage IP covering iPSC technologies.

The agreements allow Cellectis and its affiliates to research, develop, and commercialize research tools, human therapeutics, or prophylactics derived from iPSCs in a certain range of differentiated cell lineages.

Paris-based Cellectis said that it is the first company in the world to be licensed by iPS Academia Japan under this particular patent portfolio for human therapeutics and prophylactics. It added that its Ectycell subsidiary will use the technology to "engineer these cells and derive consistent lines of robust products both as tools and as therapeutics."

Financial and other terms of the agreements were not disclosed.